MNOV - NASDAQ
MediciNova, Inc.
$1.32
-1.4%MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
At a Glance
Live Snapshotmnov
Cash at End of Period
Last Annual Value
30.81M
3-Year CAGR
19%
5-Year CAGR
-12%
10-Year CAGR
3%
MediciNova, Inc. Competitors Analysis of Cash at End of Period
| Company | Cash at End of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
MediciNova, Inc. NASDAQ:MNOV | 30.81M | -15.5% | -15.5% | 2.5% | |
 Immunic, Inc. NASDAQ:IMUX | 15.48M | -30.8% | -29.2% | -12.7% | |
 Aligos Therapeutics, Inc. NASDAQ:ALGS | 18.41M | -48.6% | -37.1% | N/A | |
 Estrella Immunopharma, Inc. NASDAQ:ESLA | 1.38M | -30.7% | -19.5% | N/A | |
 MiNK Therapeutics, Inc. NASDAQ:INKT | 13.36B | 1483.1% | 221.5% | N/A | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 7.80M | 19.3% | -22.3% | N/A | |
 Cue Biopharma, Inc. NASDAQ:CUE | 27.29M | -17.5% | -15.8% | 6.2% | |
 OS Therapies Incorporated NYSE:OSTX | 5.53M | 421.7% | 132.9% | N/A | |
 vTv Therapeutics Inc. NASDAQ:VTVT | 88.93M | 111.2% | 46.0% | 5.6% | |
 Biomea Fusion, Inc. NASDAQ:BMEA | 56.18M | -31.8% | -17.4% | N/A | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 3.50M | -5.1% | -39.9% | 7.4% |
MediciNova, Inc. Fair Value Envelope
Related Guides
Continue your MNOV research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.